Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

278
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
278
Cancer Vaccines01:30

Cancer Vaccines

488
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
488
Tumor Immunotherapy01:27

Tumor Immunotherapy

639
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting tumor-associated bacteria in digestive system cancers: carcinogenic mechanisms and nano-regulate platform design.

Journal of nanobiotechnology·2026
Same author

Intranasal DNA nanocarrier vaccines with surface-patterned antigens enhance efficacy against respiratory syncytial virus.

Nature materials·2026
Same author

An inhalable microbe-oncolytic virus consortium for lung cancer treatment.

Cell reports. Medicine·2026
Same author

CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies.

Molecular cancer·2026
Same author

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Nature communications·2026
Same author

Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Related Experiment Video

Updated: Aug 24, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K

Drug conjugate-based anticancer therapy - Current status and perspectives.

Yuqi Yang1, Shuhang Wang2, Peiwen Ma2

  • 1NHC Key Laboratory of Pulmonary Immune-related Diseases, Guizhou Provincial People's Hospital, Guiyang, 550002, China.

Cancer Letters
|October 24, 2022
PubMed
Summary

Drug conjugates, including antibody-drug conjugates (ADCs), deliver potent cytotoxic agents to tumors, improving cancer treatment. Novel peptide-drug conjugates (PDCs) and polymer-drug conjugates (PolyDCs) offer alternatives to overcome ADC limitations.

Keywords:
AntibodyDrug conjugateLinkerPayloadPeptidePolymer

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.8K

Related Experiment Videos

Last Updated: Aug 24, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.8K

Area of Science:

  • Oncology
  • Pharmacology
  • Bioconjugation Chemistry

Background:

  • Drug conjugates link tumor-homing carriers to cytotoxic agents for targeted cancer cell delivery.
  • This strategy enhances therapeutic efficacy and minimizes systemic toxicity of potent drugs.
  • Antibody-drug conjugates (ADCs) represent a successful class, with 14 approved since 2000, but have inherent limitations.

Purpose of the Study:

  • To review the current landscape of drug conjugate design, construction, and clinical efficacy.
  • To highlight advancements in novel drug conjugate classes beyond ADCs.
  • To discuss how emerging conjugates address limitations associated with antibody-based systems.

Main Methods:

  • Literature review of drug conjugate research and development.
  • Analysis of design principles for various drug conjugate classes (ADCs, PDCs, PolyDCs).
  • Evaluation of clinical efficacy data and limitations of current drug conjugate therapies.

Main Results:

  • Drug conjugates have revolutionized cancer treatment by enabling targeted delivery of cytotoxic payloads.
  • ADCs have shown significant clinical success, yet face challenges related to antibody limitations.
  • Emerging peptide-drug conjugates (PDCs) and polymer-drug conjugates (PolyDCs) present promising alternatives with improved characteristics.

Conclusions:

  • Drug conjugates are a vital and evolving area in oncology, offering improved therapeutic outcomes.
  • Novel conjugate platforms like PDCs and PolyDCs are expanding treatment options and overcoming ADC-related challenges.
  • Continued research into drug conjugate design and application holds significant potential for future cancer therapies.